Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly

被引:72
作者
Aparicio, T
Desramé, J
Lecomte, T
Mitry, E
Belloc, J
Etienney, I
Montembault, S
Vayre, L
Locher, C
Ezenfis, J
Artru, P
Mabro, M
Dominguez, S
机构
[1] Hop Bichat Claude Bernard, Serv Hepatogastroenterol, APHP, F-75018 Paris, France
[2] Hop Instruct Armees Val de Grace, Med Clin, F-75005 Paris, France
[3] Hop Eurpeen Georges Pompidou, Serv Hepatogastroenterol, APHP, F-75015 Paris, France
[4] Hop Ambroise Pare, Serv Hepatogastroenterol, APHP, F-92100 Boulogne, France
[5] Inst Gustave Roussy, Serv Hepatogastroenterol, F-94805 Villejuif, France
[6] Hop Soissons, Serv Hepatogastroenterol, F-02200 Soissons, France
[7] Hop Cochin, APHP, Serv Hepatogastroenterol, F-75005 Paris, France
[8] Hop Henri Mondor, APHP, Serv Hepatogastroenterol, F-94000 Creteil, France
[9] Hop Longjumeau, Serv Hepatogastroenterol, F-91600 Longjumeau, France
[10] Hop St Antoine, APHP, Serv Oncol, F-75011 Paris, France
[11] Hop Foch, Serv Oncol, F-92150 Suresnes, France
[12] Ctr Oscar Lambret, Dept Urodigestif, F-59020 Lille, France
[13] AGEO, F-75013 Paris, France
关键词
colon cancer; elderly; chemotherapy; oxaliplatin; irinotecan;
D O I
10.1038/sj.bjc.6601310
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients. Methods. All consecutive patients over 74 years treated with oxaliplatin or irinotecan for metastatic colorectal cancer were enrolled. The tumour response was assessed every 2-3 months and toxicity was collected at each cycle according to World Health Organisation criteria. A total of 66 patients were enrolled from 12 centres. The median age was 78 years ( range, 75-88 years); 39 patients had no severe comorbidity according to the Charlson score. In total, 44 and 22 patients received oxaliplatin or irinotecan, respectively, in combination with 5-fluororuracil+/-folinic acid or raltitrexed in 64 patients. A total of 545 chemotherapy cycles were administered in first (41%), second (51%) or third line (8%). A dose reduction occurred in 190 cycles (35%). Complete response, partial response and stabilisation occurred in 1.5, 20 and 47% of patients, respectively. The median time to progression and overall survival were 6.8 and 11.2 months in first line and 6.3 and 11.6 months in second line, respectively. Grade 3 and 4 toxicity occurred in 42% of patients: neutropenia 17%, diarrhoea 15%, neuropathy 11%, nausea and vomiting 8% and thrombopenia 6%. There was no treatment-related death. In selected elderly patients, chemotherapy with oxaliplatin or irinotecan is feasible with manageable toxicity.
引用
收藏
页码:1439 / 1444
页数:6
相关论文
共 25 条
[1]   Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen [J].
André, T ;
Bensmaine, MA ;
Louvet, C ;
François, E ;
Lucas, V ;
Desseigne, F ;
Beerblock, K ;
Bouché, O ;
Carola, E ;
Merrouche, Y ;
Morvan, F ;
Dupon-André, G ;
de Gramont, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3560-3568
[2]  
Beretta G, 1997, P AN M AM SOC CLIN, V16, p259a
[3]   Estimates of cancer incidence and mortality in Europe in 1995 [J].
Bray, F ;
Sankila, R ;
Ferlay, J ;
Parkin, DM .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (01) :99-166
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]   Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy [J].
Chiara, S ;
Nobile, MT ;
Vincenti, M ;
Lionetto, R ;
Gozza, A ;
Barzacchi, MC ;
Sanguineti, O ;
Repetto, L ;
Rosso, R .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (04) :336-340
[6]   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].
Cunningham, D ;
Pyrhönen, S ;
James, RD ;
Punt, CJA ;
Hickish, TF ;
Heikkila, R ;
Johannesen, TB ;
Starkhammar, H ;
Topham, CA ;
Awad, L ;
Jacques, C ;
Herait, P .
LANCET, 1998, 352 (9138) :1413-1418
[7]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[8]   Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer [J].
deGramont, A ;
Vignoud, J ;
Tournigand, C ;
Louvet, C ;
Andre, T ;
Varette, C ;
Raymond, E ;
Moreau, S ;
LeBail, N ;
Krulik, M .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (02) :214-219
[9]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[10]  
DUCREUX M, 1999, GASTROENTEROL CLIN B, V23, pA108